Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate
Launched by AGA KHAN UNIVERSITY · Sep 7, 2013
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:All male patients undergoing ultrasound guided prostate biopsy due to any one of the following:
- • Raised prostate-specific antigen level (\>4.0ng/ml) and palpable nodularity on digital rectal examination
- • Palpable nodularity on digital rectal examination
- • Hypo echoic lesion as compared to surrounding prostate on transrectal ultrasound
- Exclusion Criteria:
- • History of previous prostate biopsy
- • Acute and/or chronic prostatitis or chronic pelvic pain syndrome
- • Anal fissure, hemorrhoids, anal surgery
- • Concomitant analgesic medication
- • Chronic renal failure
- • Allergy to diclofenac
About Aga Khan University
Aga Khan University (AKU) is a distinguished institution dedicated to improving health and education across developing regions. Established in 1983, AKU is recognized for its commitment to research excellence, particularly in clinical trials that address pressing health issues in diverse populations. With a focus on advancing medical knowledge and practice, AKU's clinical trial initiatives are designed to foster innovative solutions and enhance patient care. The university collaborates with various local and international partners, leveraging its multidisciplinary expertise to conduct rigorous research that informs public health policy and improves health outcomes in communities served by its facilities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Naveed Haroon, MBBS
Principal Investigator
Aga Khan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials